近期交易合作|阿斯利康有意购入依沃西单抗，晶泰科技与辉瑞扩大合作

药菓2025-07-07

2025近期合作 & 交易事件01艾伯维收购Capstan Therapeutics02 晶泰科技与辉瑞深化战略合作03 复宏汉霖与汉康生技就HCB101订立许可协议04 盐野义与BioVersys达成抗生素项目合作05 阳光诺和与乐旷惠霖合作开发STC00706Summit与阿斯利康就抗癌药物交易展开谈判07 腾盛博药与健康元签署抗菌新药许可协议01艾伯维收购Capstan ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549736539?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-07 18:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549736539","market":"us","top_or_hot":-1,"title":"近期交易合作|阿斯利康有意购入依沃西单抗，晶泰科技与辉瑞扩大合作","media":"药菓","content":"<div>\n<p>2025近期合作 & 交易事件01艾伯维收购Capstan Therapeutics02 晶泰科技与辉瑞深化战略合作03 复宏汉霖与汉康生技就HCB101订立许可协议04 盐野义与BioVersys达成抗生素项目合作05 阳光诺和与乐旷惠霖合作开发STC00706Summit与阿斯利康就抗癌药物交易展开谈判07 腾盛博药与健康元签署抗菌新药许可协议01艾伯维收购Capstan ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>近期交易合作|阿斯利康有意购入依沃西单抗，晶泰科技与辉瑞扩大合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n近期交易合作|阿斯利康有意购入依沃西单抗，晶泰科技与辉瑞扩大合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-07 18:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b><strong>药菓</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025近期合作 & 交易事件01艾伯维收购Capstan Therapeutics02 晶泰科技与辉瑞深化战略合作03 复宏汉霖与汉康生技就HCB101订立许可协议04 盐野义与BioVersys达成抗生素项目合作05 阳光诺和与乐旷惠霖合作开发STC00706Summit与阿斯利康就抗癌药物交易展开谈判07 腾盛博药与健康元签署抗菌新药许可协议01艾伯维收购Capstan ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b","article_id":"2549736539","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549736539","pubTimestamp":1751882490,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"02晶泰科技与辉瑞深化战略合作6月30日，晶泰科技宣布与辉瑞扩大战略合作，共同开发全新一代的分子模拟平台以驱动新药研发。07腾盛博药与健康元签署抗菌新药许可协议7月4日，腾盛博药宣布已与健康元集团签署知识产权许可及技术转移协议。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","PFE":"辉瑞","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4007":"制药","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","AZN":"阿斯利康","BK4581":"高盛持仓","BK4599":"减肥药","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4592":"伊斯兰概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"Recent transaction cooperation AstraZeneca intends to purchase ivosimab, Jingtai Technology and Pfizer expand cooperation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"PFE":1},"content_text":"2025近期合作 & 交易事件01艾伯维收购Capstan Therapeutics02 晶泰科技与辉瑞深化战略合作03 复宏汉霖与汉康生技就HCB101订立许可协议04 盐野义与BioVersys达成抗生素项目合作05 阳光诺和与乐旷惠霖合作开发STC00706Summit与阿斯利康就抗癌药物交易展开谈判07 腾盛博药与健康元签署抗菌新药许可协议01艾伯维收购Capstan Therapeutics6月30日，艾伯维将以21亿美元收购临床阶段生物公司Capstan Therapeutics。本次收购核心资产包括 CPTX2309，一种潜在的首创体内 tLNP 抗 CD19 CAR-T 疗法候选药物，目前正处于治疗 B 细胞介导的自身免疫性疾病的 1 期开发阶段。AbbVie 还将获得Capstan专有的tLNP平台，该技术旨在递送能够对特定细胞类型进行体内工程改造的 RNA 载体。Capstan TherapeuticsCapstan Therapeutics是一家明星体内CAR-T开发公司，成立于2022年，专注于利用该专有的靶向脂质纳米颗粒（tLNP）开发基于RNA（tLNP-RNA）的体内CAR-T工程。02晶泰科技与辉瑞深化战略合作6月30日，晶泰科技宣布与辉瑞扩大战略合作，共同开发全新一代的分子模拟平台以驱动新药研发。本次合作升级后，双方团队将针对辉瑞专有的化学空间，开发更精准的预测模型，并拓展该平台在小分子药物研发领域的更多应用场景。03复宏汉霖与汉康生技就HCB101订立许可协议6月30日，复宏汉霖宣布与HanchorBio Inc.（汉康生技）子公司FBD Biologics Limited 订立许可协议。根据协议，复宏汉霖将获得由汉康生技自主开发的SIRPα-Fc 融合蛋白HCB101在中国（除台湾地区）、东南亚特定国家及中东和北非地区（MENA）特定国家的开发、生产及商业化独家许可权益，以及在日本市场的优先谈判权。汉康生技有望获得1000万美元的首付款、共计1.92亿美元的潜在里程碑付款及合作区域销售分成。HCB101：为一个与IgG4-Fc连结、经过工程优化的SIRPα融合蛋白，拟用于治疗晚期实体瘤及复发难治性非霍奇金淋巴瘤，该产品目前处于1b/2a期临床试验中。上海汉科生物有限公司Shanghai Hanchor Biotech Inchttps://www.hanchorbio.com/汉康生技 （HanchorBio）是一家专注于肿瘤免疫治疗药物研发的创新药企业，核心业务围绕 SIRPα-Fc融合蛋白 等生物制剂的研发。04盐野义与BioVersys达成抗生素项目合作7月2日，盐野义（Shionogi）宣布与瑞士生物科技公司BioVersys达成合作，以500万瑞士法郎（约合630万美元）的预付款获得后者一款临床前抗生素项目BV500的权益，双方将共同推进该项目转化为临床候选药物。根据合作协议，若盐野义决定行使选择权，BioVersys有望获得高达4.79亿瑞士法郎（约合6.04亿美元）的监管和销售里程碑付款，以及分级特许权使用费。BV500：该项目旨在研发针对非结核分枝杆菌（NTM）感染的新疗法。分枝杆菌广泛存在于全球各地，可引发肺部感染，尤其多见于已患有慢性阻塞性肺疾病等肺部疾病的患者。BioVersys AGhttps://www.bioversys.com/‌BioVersys是一家瑞士生物制药公司，专注于开发新型抗菌产品以治疗多重耐药细菌感染和慢性炎症性微生物组疾病‌，其核心技术平台包括TRIC和Ansamycin Chemistry，目前处于多管线临床试验阶段。05阳光诺和与乐旷惠霖合作开发STC0077月2日，阳光诺和与上海乐旷惠霖医药签署《技术开发（合作）合同》，共同开发STC007（镇痛适应症）项目。合同总金额为2亿元。STC007：STC007是诺和晟泰自主研发的化学1类新药，属于强效KOR激动剂，主要适应症包括术后疼痛及成人慢性肾脏疾病相关的中至重度瘙痒，目前均处于II期临床阶段。上海乐旷惠霖医药科技有限公司属于乐旷医药旗下公司。从事药物研发、生产等。06Summit与阿斯利康就抗癌药物交易展开谈判7月3日，阿斯利康与Summit Therapeutics正就一项价值高达150亿美元的合作协议展开谈判。根据潜在合作框架，阿斯利康可能将获得Summit旗下实验性肺癌治疗药物ivonescimab的授权许可。依沃西单抗（Ivonescimab）：是一种四价双特异性抗体，能够同时靶向PD-1和VEGF两个关键靶点。已在中国获批治疗NSCLC。Summit 于 2022 年 12 月通过一项价值高达 50 亿美元的单独交易，从中国的康方生物获得了该药物的权利。Summit Therapeuticshttps://www.smmttx.com/Summit Therapeutics是一家专注于开发创新药物的生物制药公司，特别是在抗生素和肿瘤学领域。该公司通过自主研发和合作，推动新药的临床开发，以改善患者的生活质量。07腾盛博药与健康元签署抗菌新药许可协议7月4日，腾盛博药宣布已与健康元集团签署知识产权许可及技术转移协议。健康元集团将从腾盛博药获得在大中华区对 BRII-693 进行研究、开发和商业化的独家许可。根据协议，健康元集团将全面负责BRII-693在大中华区的开发、监管审批和商业化。腾盛博药将获得首付款，并将收到额外的开发和商业化里程碑付款，以及根据产品净销售额分级比例获得的销售分成。BRII-693：是一种在研新型合成脂肽，用于治疗多重耐药和广泛耐药（MDR/XDR）革兰氏阴性菌感染的重症患者。BRII-693是通过对多粘菌素支架进行迭代结构改造研发而成。目前处于I期临床阶段。腾盛博药生物科技有限公司https://www.briibio.com/cn/腾盛博药成立于2018年，是一家以创新药物研发为核心的企业，专注于治疗慢性疾病、感染性疾病等具有重大公共卫生负担的疾病领域。扫码关注我们药菓｜iYaoGuo图片来源于网络，版权归原作者  侵删请联系","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549736539","isCrawlerRequest":true}